Abstract: The present invention relates to compositions and methods for treating neurodegenerative diseases. In some embodiments, the present invention provides compositions for treating and preventing presbycusis.

Abstract: The invention provides compositions and methods for the treatment of glomerulonephritis. In one embodiment, the invention provides a compound of formula (I) R-L-CO—X??(I) (wherein R is a C10-24 unsaturated hydrocarbon group optionally interrupted by one or more heteroatoms or groups of heteroatoms selected from S, O, N, SO, SO2, said hydrocarbon group comprising at least 4 non-conjugated double bonds; L is a linking group forming a bridge of 1 to 5 atoms between the R group and the carbonyl CO; and X is an electron withdrawing group) or a salt thereof for use in the treatment of glomerulonephritis.

Abstract: Antimicrobial compositions and methods of using such antimicrobial compositions to provide a reduction in populations of viable microorganisms.

Abstract: The present invention relates to a new class of terpene-derived compounds having an antibiotic activity and of the formulae (I) or (II) in which A is selected from NR1, O, S, CR2R3 or R—(CH2)n—R?, wherein R and R? represent independently NH, O, S or CH2, and in which R1, R2 et R3 are substituents and n is higher than or equal to 1, in particular equal to 2. The invention relates to the compound according to both the formula (I) or the formula (II) taken individually, to mixtures of the two compounds, and to compositions, mainly therapeutic ones, comprising at least one of the compounds or said mixture. According to a particular embodiment, the compound ((I) or (II) taken individually, the mixtures of both compounds and the compositions of the invention are used in the treatment of difficult C-related digestive infections. In one particular embodiment, the compound of the formula (I) is margaucine, a compound produced by a bacterial stem.

Abstract: ?-Aminoamide derivatives useful as antimigraine agents, particularly for the treatment of head pain conditions such as migraine, cluster headache or other severe headache, are disclosed. The antimigraine agents of the invention are able to reduce or even stop the pain deriving from such conditions without, virtually, any side effects.

Abstract: Activated polymeric bicine derivatives such as, as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.

Abstract: Use of at least one material chosen from homopolymers and salts thereof of formula (I), defined herein, for moisturizing the skin, mucous membranes and/or keratin fibres, and/or as a moisturizer and/or emollient, for the skin, mucous membranes and/or keratin fibres. The invention also relates to a cosmetic or pharmaceutical composition for moisturizing the skin, mucous membranes and/or keratin fibres, comprising at least one material chosen from homopolymers and salts thereof of formula (I).

Abstract: The invention discloses the existence of cannabinoid receptors in the airways, which are functionally linked to inhibition of cough. Locally acting cannabinoid agents can be administered to the airways of a subject to ameliorate cough, without causing the psychoactive effects characteristic of systemically administered cannabinoids. In addition, locally or systemically administered cannabinoid inactivation inhibitors can also be used to ameliorate cough. The present invention also defines conditions under which cannabinoid agents can be administered to produce anti-tussive effects devoid of bronchial constriction.

Abstract: Inhibitors of the cytosolic phospholypase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formula wherein X, Z, X1, R1, R2, Ra, Rb, R3, R4 and Y are as defined in the specification.

Abstract: Pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound with the formula: 1

Abstract: Described in the present invention are a dispersion which comprises, as a dispersoid, (a) 5 to 40 wt. % of an amphipatic lipid containing, in the molecule thereof, at least one hydroxy and amide group, and (b) 2 to 55 wt. % of a surfactant in an aqueous medium; a washing-away type cosmetic composition comprising the dispersion; and a washing-away type cosmetic composition comprising (A) 0.01 to 10 wt. % of an amphipatic lipid which contains, in the molecule thereof, at least one hydroxy and amide group and having a melting point not less than 30° C. and (B) 5 to 95 wt. % of a surfactant. The dispersion according to the present invention is useful as a component of a washing-away type cosmetic composition having both an emulsion-like or pearl-lustrous appearance and low skin irritation.

Abstract: The present invention provides an extended release oral dosage form of prodrugs of gabapentin and other GABA analogs, which dosage forms exhibit reduced toxicity. The dosage forms are particularly useful in administering those prodrugs of gabapentin and other GABA analogs that are metabolized to form an aldehyde. The dosage forms of the invention are useful for treating or preventing diseases and/or disorders for which the parent gabapentin or other GABA analog are known to be therapeutically effective.

Abstract: The present invention discloses highly packed polycationic ammonium, sulfonium and phosphonium lipid compounds useful for making lipid aggregates for delivery of macromolecules and other compounds into cells. They are especially useful for the DNA-dependent transformation of cells. Methods for their preparation and use as intracellular delivery agents are also disclosed.

Abstract: An absorbent article, particularly a tampon having additives that reduce toxic shock syndrome toxin (TST-1) production is disclosed. The tampon has a combination of an effective amount of at least one oxygen inhibiting agent and an effective amount of at least one surface active agent applied to: the surface of the absorbent tampon material; the surfaces of the fibers comprising the tampon; to the tampon applicator; or any combination of the foregoing. The effective amounts of the oxygen inhibiting agent and the surface active agent are sufficient to reduce the toxin production at lease about 50%, but do not negatively affect the wearer's normal vaginal flora.

Abstract: The present invention provides discrete-length polyethylene glycol and polyethylene glycol containing compounds and methods for their preparation.

Abstract: The present invention relates to amino-alkyl derivatives for treating or preventing neuronal damage associated with neurological diseases. The invention also provides compositions comprising the compounds of the present invention and methods of utilizing those compositions for treating or preventing neuronal damage.

Abstract: A process is provided for both removing and controlling biofilms present in industrial cooling and process waters. The process provides a composition which includes the reaction products of an amino base, a formaldehyde, an alkylenepolyamine, and the ammonium salt of an inorganic or organic acid. The composition may be used to remove existing biofilms from process water equipment. Further, lower maintenance dosages may be used to maintain the equipment in a substantially biofilm-free condition.

Abstract: Described in the present invention are a dispersion which comprises, as a dispersoid, (a) 5 to 40 wt. % of an amphipatic lipid containing, in the molecule thereof, at least one hydroxy and amide group, and (b) 2 to 55 wt. % of a surfactant in an aqueous medium; a washing-away type cosmetic composition comprising the dispersion; and a washing-away type cosmetic composition comprising (A) 0.01 to 10 wt. % of an amphipatic lipid which contains, in the molecule thereof, at least one hydroxy and amide group and having a melting point not less than 30° C. and (B) 5 to 95 wt. % of a surfactant. The dispersion according to the present invention is useful as a component of a washing-away type cosmetic composition having both an emulsion-like or pearl-lustrous appearance and low skin irritation.

Abstract: The present invention relates to compounds, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone.

Abstract: The present invention provides discrete-length polyethylene glycol and polyethylene glycol containing compounds and methods for their preparation.

Abstract: An ascorbic acid-based composition and related method for the treatment of aging or photo-damaged skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at least about 5.0% (w/v) ascorbic acid and may advantageously be formulated to have a pH above 3.5. Generally, the composition also includes non-toxic zinc salt, tyrosine compound, and/or pharmaceutically acceptable carrier. In addition, the composition may include an anti-inflammatory compound, such as aminosugar and/or sulfur-containing anti-inflammatory compound. The topical composition may be in the form of a serum, a hydrophilic lotion, an ointment, a cream, or a gel.

Abstract: A method of reducing hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatologically acceptable composition containing a suppressor of the metabolic pathway for the conversion of glucose to acetyl-CoA.

Abstract: A process is provided for both removing and controlling biofilms present in industrial cooling and process waters. The process provides a composition which includes the reaction products of an amino base, a formaldehyde, an alkylenepolyamine, and the ammonium salt of an inorganic or organic acid. The composition may be used to remove existing biofilms from process water equipment. Further, lower maintenance dosages may be used to maintain the equipment in a substantially biofilm-free condition.

Abstract: Use of at least one aminothiol ester derivative for the preparation of a pharmaceutical composition intended to increase the inhibition of a character resistant to the induction of apoptosis of transformed cells, this character being due to the bc12 gene present in these cells. The pharmaceutical composition is more particularly intended to treat pathologies chosen from breast cancers, B cell lymphomas, leukaemias, neuroblastomas, adenocarcinomas of the prostate, prolactinomas and other pituitary adenomas.

Abstract: There are disclosed novel synthetic peptides of formula (I) ##STR1## where A, B, D, E, F, G, J, m, n, and p are defined in the specification. Compounds of formula (I) promote the release of growth hormone in humans and animals. Growth promoting compositions containing such compounds of formula (I) as the active ingredient, methods of stimulating the release of growth hormone, and the use of such compounds of formula (I) are also disclosed.

Abstract: A method of using compounds of formula I ##STR1## in which the C.dbd.C double bond is present in E and/or Z configuration and the variables have the following meanings:R.sup.1 denotes COOR.sup.5, COR.sup.5, CONR.sup.5 R.sup.6, CN, O.dbd.S(--R.sup.5).dbd.O, O.dbd.S(--OR.sup.5).dbd.O, R.sup.7 O--P(--OR.sup.8).dbd.O;R.sup.2 denotes COOR.sup.6, COR.sup.6, CONR.sup.5 R.sup.6, CN, O.dbd.S(--R.sup.6).dbd.O, O.dbd.S(--OR.sup.6).dbd.O, R.sup.7 O--P(--OR.sup.8).dbd.O;R.sup.3 denotes hydrogen, an optionally substituted aliphatic, cycloaliphatic, araliphatic or aromatic radical having in each case up to 18 carbon atoms;R.sup.4 denotes an optionally substituted aromatic or heteroaromatic radical containing from 5 to 12 ring atoms;R.sup.5 toR.sup.8 independently denote hydrogen, an open-chain or branched-chain aliphatic, araliphatic, cycloaliphatic or optionally substituted aromatic radical containing in each case up to 18 carbon atoms,where the variables R.sup.3 to R.sup.

Abstract: Mammalian hair growth is reduced by applying an inhibitor of aminoacyl-tRNA synthetase to the skin.

Abstract: A method of reducing hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatologically acceptable composition containing a compound that inhibits the formation of glycoproteins, proteglycans, or glycosaminoglycans in an amount effective to cause a reduction in hair growth.

Abstract: A method of reducing hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatologically acceptable composition containing a suppressor of the metabolic pathway for the conversion of glucose to acetyl-CoA.

Abstract: An antacid composition comprises, as antacid ingredients, a hydrotalcite and dihydroxyaluminium aminoacetate in such a ratio that the former/the latter equals 30/70 to 90/10 (by weight). The composition may further comprises a readily acting or rapid effecting antacid ingredient such as a magnesium hydroxide in an amount of 10 to 50% by weight. The antacid composition is improved in antacid properties and rapid effecting properties, and is useful as a pharmaceutical composition comprising the antacid composition, a carrier, an additive, an additional pharmaceutically active ingredient and so on. The total amount of the antacid ingredients in the pharmaceutical composition may be 10% by weight or more. The pharmaceutical composition may be formed into a fine granule or a granule with utilizing granulation, or into a tablet by compression-molding.

Abstract: The present invention relates to an anaesthetic veterinary pharmaceutical composition, comprising a general anaesthetic selected from phencyclidine derivatives such as ketamine or tiletamine, as well as 0.015 to 1.25 molar equivalents of selegiline, combined in a single pharmaceutical composition or presented separately.

Abstract: A pharmaceutical or cosmetic composition is disclosed comprising in combination a retinoid and a sterol capable of inhibiting the biosynthesis of cholesterol resulting in a synergistic effect in the treatment of disorders of epidermic keratinization, proliferation and/or sebaceous function.

Abstract: Described herein is the use of a substantially pure form of an oxidized polyamine, and especially spermine dialdehyde, in the treatment of tissue grafts or other organs for transplantation. The compounds and treatment are especially useful in treating grafts for bone marrow transplants, whether they be allogeneic or autograft transplants.

Abstract: Novel 2-(N-substituted-aminoalkyl)-5-(E)-alkylidene cyclopentanones, 2-(N-substituted-aminoalkyl)-5-(E)-arylalkylidene cyclopentanones, and derivatives thereof having the formula ##STR1## wherein x is methylene or ethylene; R.sub.1 is dimethylamino, diethylamino, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, anilino or substituted anilino; R.sub.2 is hydrogen, straight or branched alkyl of 1 to 9 carbon atoms, aryl or arylalkyl; R.sub.3 is hydrogen, straight or branched alkyl of 1 to 9 carbon atoms, aryl or arylalkyl; and R.sub.4 is hydrogen, methyl, ethyl, allyl, benzyl, substituted benzyl, cyclopentyl, substituted cyclopentyl, cyclopenten-1-yl, or substituted cyclopenten-1-yl; and wherein aryl is phenyl or phenyl substituted with one or more methoxyl, hydroxyl, methylenedioxy, chloro, bromo, fluoro, ethoxycarbonylmethoxy, benzoxy, alkyl group, or their combination, possess anti-inflammatory, analgesic and anticancer properties.

Abstract: A method to treat or prevent retroviral infection by administering a novel conjugate is described. Lucifer Yellow and its analogs are conjugated to compounds having carbonyl functional groups for reaction with the semicarbazide moiety of Lucifer Yellow to obtain the semicarbazone conjugate.

Abstract: This invention relates to the use of oxidized polyamines, and especially aminoaldehydes such as spermine bisaldehyde both in vitro and in vivo to elicit an immunosuppressive response in living cells. It also relates to the therapeutic application of these compounds to induce an immunosuppressive response in living organism.

Abstract: Pharmaceutical preparations for veterinary use, in the form of concentrate solutions, containing Thiamphenicol as active ingredient are described.

Abstract: A phenylalanine derivative having the formula (I): ##STR1## where R.sup.1 and R.sup.2 are independently hydrogen provided that both R.sup.1 and R.sup.2 are not hydrogen at the same time;C.sub.1 -C.sub.8 alkyl which may be substituted with hydroxy, hydroxycarbonyl, C.sub.1 -C.sub.4 alkoxycarbonyl, C.sub.1 -C.sub.4 alkylmercapto, C.sub.1 -C.sub.4 alkoxy, carbamoyl, sulfamoyl, pyridyl, or phenyl which may further be substituted with nitro, C.sub.1 -C.sub.4 alkoxy, or halogen;C.sub.6 -C.sub.8 cycloalkyl which may be substituted with hydroxy, C.sub.1 -C.sub.4 alkoxy, hydroxylcarbonyl, C.sub.1 -C.sub.4 alkoxycarbonyl, or C.sub.1 -C.sub.4 alkyl;phenyl which may be substituted with halogen, nitro, trifluoromethyl, C.sub.1 -C.sub.4 alkoxy C.sub.1 C.sub.4 alkylmercapto, C.sub.1 -C.sub.4 alkylcarbonyl, phenylcarbonyl, hydroxycarbonyl, C.sub.1 -C.sub.4 alkoxycarbonyl, carbamoyl, sulfamoyl, amidino, pyridylcarbonyl, or C.sub.1 -C.sub.6 alkyl which may further be substituted with C.sub.1 -C.sub.

Abstract: Analgesic activity is exhibited by compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof wherein R.sub.1, R.sub.2 and R.sub.4 are each independently hydrogen, alkyl, carboxyalkyl, halosubstituted alkyl, hydroxyalkyl, aminoalkyl, mercaptoalkyl, alkylthioalkyl, (cycloalkyl)alkyl, (heteroaryl)alkyl, arylalkyl, carbamoylalkyl, guanidinylalkyl, or heteroaryl, and R.sub.3 is hydroxymethylene or carbonyl.